International Journal of Epilepsy 2015; 02(02): 101-105
DOI: 10.1016/S2213-6320(15)00063-9
Original Article
Thieme Medical and Scientific Publishers Private Ltd.

Phenobarbitone: Indian Epilepsy Society- Consensus Document

Man Mohan Mehndiratta
a  Janakpuri Super Speciality Hospital, New Delhi
,
Satish Jain
b  Indian Epilepsy Centre, New Delhi
,
Parampreet S. Kharbanda
c  Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh
,
Pravina Shah
d  Fortis Hospital, Mulund, Mumbai, Maharashtra
,
Manjari Tripathi
e  All India Institute of Medical Sciences New Delhi
,
Sita Jayalakshmi
f  Krishna Institute of Medical Sciences, Secunderabad, Telangana
,
Sheffali Gulati
g  All India Institute of Medical Sciences, New Delhi
,
Suvasini Sharma
h  Lady Hardinge Medical College and Associated Kalawati Saran Children's Hospital, New Delhi
,
Sangeeta Ravat
i  Seth G.S. Medical College and King Edward Memorial Hospital Mumbai
› Author Affiliations

Subject Editor:
Further Information

Publication History

Publication Date:
06 May 2018 (online)

  

Epilepsy is a common neurological disorder affecting 65 million people worldwide and approximately more than 12 million in India. Two-third of the people with epilepsy lives in resource-limited countries. Phenobarbitone was the first anti-epileptic drug (AED) used in 1912 and has been in use for more than 100 years now. Its low cost and favorable cost-efficacy ratio, which is lower than any other AED in current use, makes the drug particularly suitable for use in the low- and middle-income countries. [[1]] The World Health Organization (WHO) recommends phenobarbitone as a first-line treatment for convulsive seizures in resource-poor countries and includes it in its Essential Drug List. [[2]] However, the use of phenobarbi-tone is largely limited owing to the concerns regarding its cognitive and behavioral side effects especially in children. This article summarizes the current role of phenobarbitone in the treatment of epilepsy.

[Tables 1]-[5]